Core Viewpoint - On the day of its resumption of trading, NuoTai Bio faced a valuation downgrade from fund companies due to financial fraud allegations, with a significant reduction in stock price estimates [2][4][6] Group 1: Valuation Adjustments - On July 22, 2023, China Merchants Fund announced a valuation adjustment for NuoTai Bio's stock to 32.78 yuan, representing a 20% decrease from the pre-suspension price of 40.98 yuan [2][6] - As of the end of Q2 2023, a total of 19 funds from 8 fund companies held 9.23 million shares of NuoTai Bio, indicating a reduction of 5.26 million shares compared to the previous quarter [6] Group 2: Regulatory Actions - NuoTai Bio received a notice from the China Securities Regulatory Commission (CSRC) on July 18, 2023, regarding two violations: false reporting in the 2021 annual report and significant false content in public offering documents [8][9] - The company was found to have inflated its revenue by 30 million yuan and profit by 25.95 million yuan in its 2021 annual report, which constituted 20.64% of the total profit disclosed for that period [9] - The CSRC imposed a fine of 47.4 million yuan on NuoTai Bio, and the actual controller and several executives were also penalized [9]
复牌“摘帽”！基金公司第一时间“下调”
Zhong Guo Ji Jin Bao·2025-07-22 06:29